Searchable abstracts of presentations at key conferences in endocrinology

ea0032p35 | Adrenal cortex | ECE2013

A national survey on the prevalence and treatment outcome of active Cushing’s disease in Belgium

Bex Marie , Nauwelaerts Heidi , T'Sjoen Guy , Velkeniers Brigitte , Corvilain Bernard , Abrams Pascale , Beckers Albert , De Block Christophe , Maiter Dominique

To estimate the point prevalence of active Cushing’s disease (CD) in Belgium, all endocrinologists were invited to perform a retrospective chart review of the CD patients they had been treating between 1-1-2009 and 31-12-2010.Only patients requiring cortisol lowering therapy because of cortisol excess could be included, such as de novo patients (n=53), previously diagnosed patients with persisting/recurrent disease after pituitary surgery a...

ea0063p737 | Pituitary and Neuroendocrinology 2 | ECE2019

A multicentre, randomized, open-label, Phase IV study investigating management of pasireotide-associated hyperglycaemia with incretin-based therapy or insulin in patients with acromegaly or Cushing’s disease (CD)

Bolanowski Marek , Gu Feng , Feldt-Rasmussen Ulla , Zhang Shaoling , Yu Yerong , Witek Przemyslaw , Pedroncelli Alberto M , Nauwelaerts Heidi , Jabbour Nadine , Paul Michaela , Samson Susan

Background: Pasireotide has proven efficacy in acromegaly and CD, although pasireotide-associated hyperglycaemia occurs in some patients. This Phase IV, randomized, open-label study investigated optimal management of pasireotide-associated hyperglycaemia uncontrolled by metformin/oral antidiabetic therapy (OAD) [NCT02060383].Methods: Adults with acromegaly or CD were enrolled and treated with long-acting pasireotide 40 mg/28 days or subcutaneous pasireot...